Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Respiration

• Publication date

  2012-07-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000338790PMID 22797485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

  2012cited by this paper
• Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

  2011cited by this paper
• Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Quantification of Circulating Cell-Free DNA in the Serum of Patients with Obstructive Sleep Apnea–Hypopnea Syndrome

  2010cited by this paper
• Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.

  2009cited by this paper
• Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009cited by this paper
• Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer

  2009cited by this paper
• TNM Classification of Malignant Tumours, 7th Edition

  2009cited by this paper
• Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

  2007cited by this paper
• Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)

  2007cited by this paper
• PD2-3-3: High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)

  2007cited by this paper
• High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)

  2007cited by this paper
• Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

  2006cited by this paper
• Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay

  2006cited by this paper
• EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer

  2006cited by this paper
• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

  2005cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

  2001cited by this paper

• Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures

  2025cites this paper
• A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer

  2024cites this paper
• Prognostic and predictive significance of soluble programmed death ligand 1 in bronchoalveolar lavage fluid in stage IV non-small cell lung cancer

  2024cites this paper
• The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

  2023cites this paper
• Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic Review

  2022cites this paper
• Interpretation of Lung Cancer Plasma EGFR Mutation Tests in the Clinical Setting.

  2022cites this paper
• Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma

  2022influential citation
• Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer

  2022cites this paper
• Concordance of Epidermal Growth Factor Receptor Mutation from Tissue Biopsy and Plasma Circulating Tumor DNA in Treatment-Naïve Lung Adenocarcinoma Patients

  2022cites this paper
• The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer

  2022cites this paper
• Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma

  2021cites this paper
• Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer

  2021cites this paper
• The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments

  2021cites this paper
• Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective.

  2021cites this paper
• Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer

  2021cites this paper
• The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer

  2021influential citation
• Prevalence and Patterns of EGFR Mutations in Non-Small Cell Lung Cancer in the Middle East and North Africa: A Systematic Review

  2021cites this paper
• Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations

  2021influential citation
• Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

  2020cites this paper
• Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer

  2020cites this paper
• The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies

  2020cites this paper
• Tumorspheres as an in vitro model for cancer stem-like cell characterization in non-small cell lung cancer. Prognostic implications

  2020cites this paper
• Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports

  2020cites this paper
• Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation

  2020cites this paper
• Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review.

  2019cites this paper
• Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine.

  2019cites this paper
• Opportunities of circulating tumor DNA in lung cancer.

  2019cites this paper
• Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.

  2019cites this paper
• INVITED REVIEW SERIES: MOLECULAR TECHNIQUES FOR RESPIRATORY DISEASES

  2019cites this paper
• Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer

  2019cites this paper
• Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?

  2018cites this paper
• Are liquid biopsies a surrogate for tissue EGFR testing?

  2018cites this paper
• Update on the types and usage of liquid biopsies in the clinical setting: a systematic review

  2018cites this paper
• Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis

  2018influential citation
• Cell-Free DNA Utility and Value of Recommendation.

  2018cites this paper
• Cytostatic hydroxycoumarin OT52 induces ER/Golgi stress and STAT3 inhibition triggering non-canonical cell death and synergy with BH3 mimetics in lung cancer.

  2018cites this paper
• Role of circulating tumor DNA in the management of early‐stage lung cancer

  2018cites this paper
• Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer

  2018cites this paper
• Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer ( Liquid Biopsy ) Policy

  2018cites this paper
• Tissue or blood: which is more suitable for detection of EGFR mutations in non-small cell lung cancer?

  2018influential citation
• Cancer Biomarkers: Important Tools for Cancer Diagnosis and Prognosis

  2017cites this paper
• Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)

  2017cites this paper
• Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China

  2017cites this paper
• Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine

  2017cites this paper
• Tissue or blood: which is more suitable for detection of EGFR mutations in non-small cell lung cancer?

  2017cites this paper
• Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.

  2017cites this paper
• Circulating DNA in EGFR-mutated lung cancer.

  2017cites this paper
• Utility of Liquid Biopsy by Improved PNA‐LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non–Small‐Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice

  2017cites this paper
• The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?

  2017cites this paper
• Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis

  2017cites this paper
• Next Generation Point-of-care Biomedical Sensors Technologies for Cancer Diagnosis

  2017cites this paper
• The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC

  2017cites this paper
• Technologies for analysis of circulating tumour DNA: Progress and promise

  2017cites this paper
• Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management

  2017cites this paper
• lasma epidermal growth factor receptor mutation testing with a hip-based digital PCR system in patients with advanced non-small ell lung cancer

  2017cites this paper
• Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay

  2017cites this paper
• Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer

  2016cites this paper
• Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR

  2016cites this paper
• ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

  2016cites this paper
• Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer

  2016cites this paper
• The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

  2016cites this paper
• Liquid Biopsy in Non-Small Cell Lung Cancer

  2016cites this paper
• Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

  2016cites this paper
• EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

  2016cites this paper
• Tumor volume determines the feasibility of cell‐free DNA sequencing for mutation detection in non‐small cell lung cancer

  2016cites this paper
• EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment

  2016influential citation
• Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

  2016cites this paper
• Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

  2016cites this paper
• The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy

  2016cites this paper
• Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

  2016cites this paper
• Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.

  2016cites this paper
• [Free circulating DNA as a tool for lung cancer patients management].

  2016cites this paper
• 非小细胞肺癌外周血游离DNA及肿瘤细胞EGFR基因突变检测方法的研究进展

  2016cites this paper
• FEP Medical Policy Manual

  2016cites this paper
• Extracellular Nucleic Acids and Cancer

  2015cites this paper
• Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing.

  2015cites this paper
• Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status.

  2015cites this paper
• Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis.

  2015cites this paper
• Role of circulating-tumor DNA analysis in non-small cell lung cancer.

  2015cites this paper
• Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

  2015cites this paper
• Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma

  2015cites this paper
• The frequency of epidermal growth factor receptor mutations in non-small-cell lung cancer patients from Egypt

  2015cites this paper
• Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer

  2015influential citation
• The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer

  2015cites this paper
• Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

  2015cites this paper
• Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

  2015cites this paper
• Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

  2015cites this paper
• Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer

  2015cites this paper
• EGFR mutations in lung cancer: from tissue testing to liquid biopsy.

  2015cites this paper
• Detection of epidermal growth factor receptor mutation in plasma as a biomarker in chinese patients with early-stage non-small cell lung cancer

  2015cites this paper
• Detection of epidermal growth factor receptor mutation in plasma as a biomarker in chinese patients with early-stage non-small cell lung cancer

  2015cites this paper
• Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer

  2015cites this paper
• A comparison of consistency of detecting c-MET gene amplification in peripheral blood and tumor tissue of nonsmall cell lung cancer patients.

  2015cites this paper
• Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma

  2014cites this paper
• Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

  2014cites this paper
• Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

  2014cites this paper
• Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

  2014cites this paper
• Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib

  2014cites this paper
• Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

  2014cites this paper
• Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

  2014cites this paper